Q-omics provides the consensus-scored SCGB1C1 profile across patient tissues and cancer cell-line models. SCGB1C1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SCGB1C1 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, SCGB1C1 RNA expression shows 7,255 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, KIRC, and TGCT as cancer lineages where SCGB1C1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCGB1C1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCGB1C1 survival associations across molecular data types. SCGB1C1 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCGB1C1 RNA expression–survival associations across cancer types. High SCGB1C1 expression shows unfavorable associations in KICH, ACC and SCLC, but favorable associations in HNSC, CESC and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SCGB1C1 RNA expression.
This table summarizes SCGB1C1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SCGB1C1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCGB1C1 shows lower tumor expression in KIRC, KICH, KIRP, LUAD and COAD. The KIRC box plot shows higher SCGB1C1 RNA expression in normal versus tumor tissue (log2 FC = −0.132, t-test p < 0.001).
This table shows molecular features associated with SCGB1C1 in patient tissues and cancer cell lines. In patient samples, SCGB1C1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SCGB1C1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
